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ABSTRACT 
 
There are  particular characteristics of Medical Devices, such as the device-
user interaction, the incremental nature of innovation and the broader 
organizational impact that lead to additional challenges for health technology 
assessment (HTA). The project explored key aspects of the conduct and 
methods of HTA for MDs. Systematic reviews and original research studies 
were conducted to determine improvements in processes and methods that 
could enhance the potential for HTA and optimize the diffusion of MDs.  
Regulatory processes for MDs should be more closely aligned, the HTA 
evaluative framework should be harmonized and processes for conditional 
coverage and evidence development should be used. The methods for HTA 
should consider MDs as complex interventions, require the establishment of 
high quality registries, consider an iterative approach to the evaluation over 
time, recognize and allow for the particular characteristics of devices and use 
appropriate approaches for confounder adjustment in comparative 
effectiveness studies. To optimize the diffusion a common classification 
should be developed across countries in order to facilitate international 
comparisons, factors driving diffusion should be explored in HTA reports and 
physicians’ personal goals and motivation should be better understood. 
The key recommendations of the MedtecHTA project should improve the 
conduct and use of HTA for MDs. 
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1. Introduction 
In this paper we present the key recommendations from the MedtecHTA 
project, organized under three themes (i) improving the process for HTA of 
medical devices (ii) developing methods for HTA of medical devices and (iii) 
optimizing the diffusion of medical devices. In each case we outline the issues 
that the recommendations seek to address, followed by the recommendations 
themselves. The research underpinning them is described in the papers 
emanating from the respective work packages, including the other papers in 
this supplement.  
 
2. Improving the process for HTA of medical devices  
The major issues identified regarding the process for the HTA of medical 
devices were that (i) the procedures for granting market access to new 
devices did not always encourage the generation of the clinical data, prior to 
product launch, necessary to undertake reliable HTAs, and (ii) that the 
specific characteristics of medical devices (eg the learning curve) were not 
explicitly considered in the methods guidelines of those organizations 
conducting HTAs. Furthermore, since the clinical evidence base is often not 
mature when devices are granted market access, an approach that 
encourages the generation of more data after product launch is required.  
In their paper in this supplement, Ciani et al (2016) argue that (i) more 
stringent requirements supported by appropriate methodological choices are 
needed to provide clinical trial data for high-risk devices (ii) post-marketing 
surveillance based on device and user real world data should be encouraged 
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(iii) international harmonisation of practices will benefit the manufacturers and 
(iv) progressive alignment of regulatory and HTA evaluation for parallel 
submissions will improve efficiency in the health systems and promote timely 
access to affordable effective technologies. 
Additionally, in their paper Rothery et al (2016) point out the issues relating to 
uncertainty and the value of research specific to devices: learning curve effects, 
incremental device innovation, investment and irrecoverable costs, and dynamic 
pricing.  They show the circumstances under which requiring additional research 
after product launch, accompanied by conditional approval for reimbursement, 
may be an appropriate policy choice.  They also show how the value of additional 
research might be shared between the manufacturer and health sector to help 
inform who might reasonably be expected to conduct the research needed. 
Against this background, we make the following recommendations. 
 
Recommendations A: Improving the process for HTA of medical devices 
 
A1. Align regulatory and HTA processes for devices with respect to data 
requirements, through: 
- joint scientific advice by regulatory and reimbursement bodies for data 
collection for the device industry 
- designing studies that allow collection of data on effectiveness that 
jointly fulfill the requirements of regulators and payers  
 
A2. Harmonize the HTA evaluative framework (collection & synthesis of 
clinical evidence and economic evaluation) for devices across international 
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HTA agencies, through:  
- developing a standardized international risk classification for MDs 
- determining appropriate levels of evidential requirements by risk 
category 
 
A3. Recognize that assessment of expected cost-effectiveness is not 
sufficient: conditional coverage and evidence development decisions should 
be assessed 
- the value of the device and future value of research needs to be 
quantified and used to identify the optimal timing of reimbursement 
decisions in the device’s life cycle 
- implementation may commit resources that cannot be recovered 
 
A4. Consider the implications of the learning curve (LC) on policy decisions 
(and vice versa) 
- the LC does not only change the estimate of effectiveness but also 
affects the uncertainty in the decision 
- identify the mechanisms of learning likely to cause change over time 
and assess the profile of investment risk according to user experience 
affected by the rate of uptake of the device in practice 
 
A5. Consider the likely prospects of research and who should pay for it 
           - is it priority for public funding or for manufacturers to undertake? 
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3. Developing methods for HTA of medical devices  
The methods for assessing the clinical and cost-effectiveness of medical 
devices need to adhere to the general standards for all health technologies, 
but also take account of the specific characteristics of medical devices. These 
include the existence of the learning curve, incremental innovation, dynamic 
pricing and organizational impact. The reviews of the literature conducted for 
the MedtecHTA project found that, although the general standards were good, 
more attention needs to be paid to these specific characteristics. In terms of 
the assessment of comparative effectiveness, it is best to consider 
procedures involving the use of medical devices to be ‘complex interventions’. 
In terms of economic evaluation, the changes due to the learning curve, 
incremental innovation, dynamic pricing and organizational impact need to be 
modeled adequately. 
Other key challenges relate to the relative lack of randomized controlled trials, 
as compared with pharmaceuticals, and the inherent uncertainty about clinical 
and cost-effectiveness at the time of product launch. Therefore, efforts may 
be necessary to collect data on safety and effectiveness post-launch. In 
addition, because of the likely reliance on observational studies, such as 
registries, appropriate methods of bias-adjustment need to be applied. Finally, 
the decision to approve, or not approve, a new device for reimbursement is 
closely linked to the decision on whether to collect more data and the nature 
of the data collected. 
In their paper in this supplement, Schnell-Inderst et al (2016) consider medical 
devices to be complex interventions and argue that evaluation of their clinical 
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effectiveness differs in some aspects from the evaluation of pharmaceuticals. 
One of the main challenges they identify is the lack of robust evidence and a 
need for combining experimental and observational studies (OS) in 
quantitative evidence synthesis accounting for internal and external biases. 
They address this challenge by performing an elicitation exercise to determine 
the strength of belief of methodological and clinical experts regarding the size 
of internal and external bias affecting estimates of treatment effect estimates. 
These bias-adjusted treatment effects were then fed into a generalized 
evidence synthesis. In the evidence synthesis, they applied frequentist and 
Bayesian statistical models using relative risks with 95% confidence/credibility 
intervals as effect estimates. 
Although such bias-adjusted estimates of treatment effects can be useful for 
economic evaluations in situations where there is a relative lack of controlled 
clinical studies, economic studies also need to consider the effects, on costs 
and benefits, of the particular characteristics of medical devices, such as the 
learning curve, incremental innovation and organizational impact. In their 
paper in this supplement, Tarricone et al (2016) point to the inadequacies in 
existing economic evaluations and make recommendations for improvements 
in future studies. 
A major challenge is to obtain an accurate estimate of the impact of the 
learning curve. In their paper in this supplement, Varabyova et al (2016) 
demonstrate how this can be done by using administrative data on over 
40,000 patients admitted with unruptured abdominal aortic aneurysm to 553 
different hospitals over the years 2006 to 2013. They examine two patient 
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outcomes, namely, in-hospital mortality and length of stay (LOS) using 
hierarchical regressions with random effects at the hospital level. The 
estimated models control for patient and hospital characteristics and take 
learning interdependencies between endovascular aneurysm repair (EVAR) 
and fenestrated EVAR (fEVAR) into account. They argue that to foster the 
consideration of learning in economic evaluations of medical devices a 
general framework for estimating learning effects needs to be devised. 
Finally, in their paper, Rothery et al (2016) develop a general framework for 
considering the uncertainties in the economic evaluation of devices and 
linking the gathering of additional information with policies on approval for 
reimbursement.  
Against this background, we make the following recommendations. 
 
Recommendations B: Developing methods for HTA of medical devices 
B1. Refine existing methods (for collection and synthesis of clinical and 
economic data) for handling the common ‘complexities’ of devices, including: 
- synthesis of observational and trial evidence 
- incorporating learning curves into decision analytic models 
- recognizing the potential for incremental innovation 
  
B2. Consider the MD-related intervention as a complex intervention; in 
particular, include the intervention’s components and the relation between 
intervention, modifying factors and outcome in the formulation of the research 
question 
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B3. Consider specific study designs and analysis methods, in addition to 
general recommendations for RCTs, in order to assess the comparative 
effectiveness of MDs 
- these approaches should address challenges often associated with 
devices, including rapid incremental development, the device/user 
interface and effect modification by contextual factors 
 
B4. Establish disease-based or device-based registries of high quality for the 
long-term study of the effectiveness and safety of MDs. 
 
B5. Design such registries to allow comparative analyses:  
- routinely collecting information on possible confounding factors 
- collecting information on treatment patterns to facilitate HTA 
  
B6. Use appropriate methods for confounder adjustment in comparative 
effectiveness or safety analyses and try to address residual confounding 
 
B7. If data from large registries are available for inclusion in the evidence 
synthesis in HTA, consider bias-adjustment based on expert elicitation as one 
scenario in the sensitivity analysis.  
 
B8. Document research using suitable existing reporting guidelines. 
 
B9. Consider MD-specific application of guidance on the methods for 
evidence synthesis from the framework on complex interventions. 
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B10. Assess the applicability of findings considering the challenges arising 
from patient eligibility, user dependence, study design, and rapid evolution of 
the technology 
 
B11. In economic evaluations and HTAs of MDs, pay particular attention to 
the particular characteristics of MDs and explore their quantitative impact on 
cost-effectiveness as part of the study. 
   
B12. Consider an iterative process to the evaluation of devices as additional 
evidence and learning emerges over time 
 
B13. Consider the likelihood of future price changes 
- price influences the benefits of early approval and the benefits of 
additional research 
- it may be useful to identify effective price thresholds for which guidance     
changes 
 
B14. Determine whether manufacturers should be expected to conduct the 
research, based on an assessment of: 
- the commercial value to manufacturers of early evidence 
- the potential for Approval with Research and for improving research  
timelines 
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4. Optimizing the diffusion of medical devices  
Optimizing the use of medical devices would involve ensuring that they are 
used only in situations where they are clinically and cost-effective. The review 
of the literature conducted in the MedtecHTA project showed that there are 
wide geographical variations in the use of implantable cardiac devices, but 
very little understanding of why these variations exist. In order to obtain a 
better understanding of the use of devices, it is important to have 
standardized methods of data collection, so that differences between regions 
and countries can be reliably studied. 
In their paper in this supplement, Torbica et al (2016) report the first 
investigation of the determinants of temporal and geographical variations in 
pacemaker (PM) and implantable cardioverter defibrillator (ICD) implants and 
replacements at regional level across 5 EU countries. They found that (i) 
regional per capita GDP appears to have no effect on implant rates of cardiac 
implantable electrical devices (CIEDs) (ii) regions with greater proportion of 
residents with higher level of tertiary education, an aged population, and 
greater life expectancy have higher implant rates of CIEDs and (ii) higher 
numbers of implanting centres foster access to technologies. 
This last finding suggests that it is important to gain a better understanding of 
the clinical, professional and organizational factors that encourage or 
discourage the use of the clinical procedures involving the use of devices. 
Therefore, more study is required of the motivational factors facing patients, 
physicians and the institutions in which they work. In addition, attention needs 
to be paid to the relevant demographic factors and the impact of health care 
financing and organization. 
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Therefore, in their paper in this supplement, Hatz et al (2016) conducted a 
comprehensive analysis to investigate which environmental, organizational, 
individual and technological factors impact the adoption and utilization of 
cardiovascular devices. The data were collected from a large-scale online 
survey that was sent to members of the European Society of Cardiology. 
Seven random intercept hurdle models were estimated using the data 
obtained from the survey. They found that better manufacturer support 
increased the adoption probability of “new” devices (i.e., in terms of CE mark 
approval dates), that budget pressure increased the adoption probability of 
“old” devices and that larger hospitals and urban locations were associated 
with higher adoption probabilities across devices. Other variables, such as 
financial aspects, motivation or organizational effects of adoption, were not 
statistically significant across models, suggesting that these factors are less 
important than other factors for the adoption of devices.  
Against this background, we make the following recommendations. 
 
Recommendations C: Optimizing the diffusion of medical devices 
 
C1. Leverage routinely collected data (administrative data) to investigate the 
adoption and diffusion of MDs, provided that coding system allows for valid 
and reliable identification of the technology 
 
C2. Endorse the use of a common classification for medical devices (unique 
identification code) across countries to facilitate international comparisons   
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C3. Include factors driving adoption of medical devices systematically in HTA 
reports to estimate the impact of the interplay of:  
- physician characteristics,  
- organizational, regional, environmental factors and manufacturers’ 
actions  
 
 C4. Consider divergent effects by stratifying by medical devices type (e.g. 
“old” and “new” medical devices) 
 
C5. Concentrate on the identification of key opinion leaders in hospital to 
better understand the adoption and the diffusion process  
 
C6. Focus on developing the understanding of physicians’ personal goals and 
motivation and their role in the adoption of medical devices 
 
C7. Monitor manufacturers’ actions, as they seem to be very relevant for the 
adoption of “new” medical devices 
 
C8. Consider regional (e.g. rural vs urban hospital location) and 
environmental factors (e.g. GDP and out-of-pocket payment) to understand 
where the diffusion process is likely to take place 
- in large hospitals, with relatively large specialist departments 
- in high income countries with lower shares of out-of-pocket payments 
 
5. Future research  
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Although the recommendations made by the MedtecHTA project will go a long 
way towards improving the conduct and use of HTA for medical devices, the 
project also identified several possible future research initiatives. 
 
5.1 Developing innovative approaches for the assessment of devices 
One of the recommendations made to improve the process for HTA of MDs 
concerned the collection of data on effectiveness that jointly fulfill the 
requirements of regulators and payers. One way of achieving this would be to 
encourage regulators and payers to work more closer together. A number of 
European collaborations already exist in the area of safety monitoring, such 
as the European Databank on Medical Devices 
(https://cemarking.net/european-databank-for-medical-devices-to-boost-
control/). The research in MedtecHTA identified some innovative approaches 
for integrating the regulatory and health technology assessment, such as the 
EXCITE programme in Ontario, Canada (https://www.marsdd.com/systems-
change/mars-excite/mars-excite/). In this programme, the data needs of future 
HTA are anticipated early in the regulatory process. 
In addition, whilst the MedtecHTA project established that the special 
characteristics of MDs suggested some differences in the approach to HTA as 
compared with pharmaceutical, further research is required to determine 
which of these needs can be met by changes in organization and process, or 
whether they require a completely different methodological approach. 
 
5.2 Estimating learning curves for medical devices 
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The case study conducted as part of the project demonstrated that it is 
possible to model the learning curve for devices. Since ideally it would be 
desirable to predict the likely impact of the learning curve for a new device, 
further research should be conducted to explore whether it is possible to 
categorize devices in terms of their likely learning curve (eg according to 
types of technologies (diagnostic or therapeutic), medical specialties, device 
risk classes or a combination of different criteria). Then, if a new device were 
developed in a given category, one might be able to predict its learning curve 
in advance. Apart from helping determine the most appropriate approach to 
determining the need for further research, this has organizational implications, 
such as determining whether more complex devices should be concentrated 
in a small number of centres, where users can be adequately trained. In fact, 
the learning effect does not attain to the use and experience with the new 
device only but often also refers to a more complex system of attributes such 
as the quality and quantity of clinical teams (eg level of training, incentives to 
innovation), the level of capital equipment present in healthcare centres, the 
types of centres and how they are organized and managed (e.g. district 
hospitals vs independent trusts, models of care based upon levels of intensity 
vs medical specialties). To investigate the learning effect of medical devices 
as exclusively depending upon number of procedures delivered by clinicians 
can therefore be a narrow approach. The learning curve may reach its steady 
state with a relatively low number of procedures but with a high attention to 
patients’ selection or with a good level of interactions between clinical teams 
in the hospitals (eg interventional cardiologists and surgeons for cardiac 
procedures implying new cardiac devices). Further research aimed at 
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investigating and measuring the impact of learning curve onto costs and 
outcomes of the introduction of medical devices need therefore to identify all 
potential explicative variables as independent variables to be included in the 
model. 
 
5.3 Use of observational data in assessing the comparative effectiveness of 
devices 
The case study on the use of bias-adjustment should be repeated for other 
devices in order to confirm its promise. In addition, while the case study 
considered bias-adjustment in a situation where there was evidence from both 
RCTs and observational data, in many situations there may only be 
observational data. Therefore, future research could explore the use of these 
methods in those situations, particularly if an RCT were planned or ongoing in 
order to compare with the results of the bias-assessment based only on the 
observational data. 
 
In addition, although registries are commonly used to assess the safety and 
longevity of devices, further research is required to determine how the design 
of such registries would need to be adapted to facilitate economic evaluation. 
A critical feature would be for registries to be able help us assess the relative 
effectiveness of treatments. In order to do so there needs to be treatment 
variation, for example patients with similar characteristics receiving different 
treatments within the registry. In addition, the risk categories of patients 
should be classified in order to enable assessments of cost-effectiveness by 
sub-groups, details of resource use are also required and, if important for the 
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treatment choice(s) being examined, the quality of life of patients should be 
measured. 
 
5.4 Studying the diffusion of devices 
The research in the project has added to our understanding of the factors 
influencing the diffusion of devices, but there is still a large amount of 
unexplained variation. Further research could be undertaken to explore the 
extent to which the observed rates of device utilization were consistent with 
research-based clinical guidelines where these exist. Further studies should 
also investigate the impact on diffusion of the motivational factors facing 
patients, surgeons and the institutions in which they work. Previous studies on 
diffusion of medical technologies had pointed to the key roles of social 
networks and peer communications rather than clinical guidelines and 
published evidence (Rogers, 1995). However in recent times the role of 
evidence has gained more attention and has become crucial for regulatory 
and HTA bodies and for the scientific ommunity at large. Today, variables 
other than peer communication can influence clinicians’ beliefs and attitude 
towards the introduction of new medical technologies and need to be 
investigated in order to achieve a better understanding of how the diffusion 
process is evolving across time and across different jurisdictions. 
 
5.5 Coverage with evidence development for medical devices 
The research in the project set out a conceptual framework for the 
assessment of policies for coverage with evidence development. Further 
research could explore the actual implementation of such policies and explore 
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practical issues such as determining who should fund the research and issues 
of study design. This is important in order to ensure the appropriate diffusion 
of devices that have the potential to be clinical and cost-effective. 
 
6. ConclusionsThe use of Health Technology Assessment has grown 
dramatically worldwide over the last 20 years in order to determine the 
appropriate level of reimbursement and coverage of medical technologies. 
Nevertheless HTA has diffused having pharmaceuticals in mind. Recent 
changes in the regulation of medical devices together with the fast pace of 
innovation that characterize the industry of medical devices have turned the 
attention to this class of medical technologies and raised the issue of whether 
methods to assess pharmaceuticals effectively fit this other type of 
technologies. While there is agreement on the consideration that medical 
devices are different from drugs, it is not entirely clear whether these 
difference really matter. 
The project MedtecHTA has revealed that medical devices’ key features make 
their assessment more challenging than drugs and need to be considered in 
order to correctly inform final policy recommendations.  
Based on multiple methods, MedtecHTA has developed a three-year research 
agenda aimed at improving current methods to assess MDs by issuing 
several recommendations. Regulatory processes for MDs should be more 
closely aligned, the HTA evaluative framework should be harmonized and 
processes for conditional coverage and evidence development should be 
used. The methods for HTA should consider MDs as complex interventions, 
require the establishment of high quality registries, consider an iterative 
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approach to the evaluation over time, recognize and allow for the particular 
characteristics of devices and use appropriate approaches for confounder 
adjustment in comparative effectiveness studies. To optimize the diffusion a 
common classification should be developed across countries in order to 
facilitate international comparisons (GHTF, 2012), factors driving diffusion 
should be explored in HTA reports and physicians’ personal goals and 
motivation should be better understood. 
Taken together, the key recommendations of the MedtecHTA project should 
improve the conduct and use of HTA for MDs. Several actors have been 
identifies as relevant to improving the assessment of MDs. Regulatory bodies, 
clinicians, patients, policy-makers, healthcare managers and analysts are all 
called to play their part and to converge towards these key principles.  
If any of the recommendations are implemented it will be important to assess 
their impact. For example, will the various initiatives to encourage the 
generation of more timely and higher quality medical evidence on MDs lead to 
their more appropriate adoption and diffusion? Such evidence will be 
important if the HTA of medical devices is to continue to develop. 
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